[go: up one dir, main page]

WO1996041621A2 - Dispositifs de liberation osmotique recouverts d'une couche mince impermeable a la vapeur - Google Patents

Dispositifs de liberation osmotique recouverts d'une couche mince impermeable a la vapeur Download PDF

Info

Publication number
WO1996041621A2
WO1996041621A2 PCT/US1996/009728 US9609728W WO9641621A2 WO 1996041621 A2 WO1996041621 A2 WO 1996041621A2 US 9609728 W US9609728 W US 9609728W WO 9641621 A2 WO9641621 A2 WO 9641621A2
Authority
WO
WIPO (PCT)
Prior art keywords
recited
beneficial agent
osmotic device
water
osmotic
Prior art date
Application number
PCT/US1996/009728
Other languages
English (en)
Other versions
WO1996041621A3 (fr
Inventor
Scott M. Herbig
Eric J. Miller
Original Assignee
S.C. Johnson & Son, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S.C. Johnson & Son, Inc. filed Critical S.C. Johnson & Son, Inc.
Priority to AU61070/96A priority Critical patent/AU6107096A/en
Publication of WO1996041621A2 publication Critical patent/WO1996041621A2/fr
Publication of WO1996041621A3 publication Critical patent/WO1996041621A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J4/00—Feed or outlet devices; Feed or outlet control devices
    • B01J4/04—Feed or outlet devices; Feed or outlet control devices using osmotic pressure using membranes, porous plates

Definitions

  • Osmotic-delivery systems typically operate by imbibing water through a membrane into a core that contains an osmotically active agent (osmagent) and a beneficial agent; the imbibed water causes an increase in hydrostatic pressure within the core, and the beneficial agent is then released by being pumped out through a delivery port or by rupture of the membrane.
  • osmotically active agent osmagent
  • beneficial agent is then released by being pumped out through a delivery port or by rupture of the membrane.
  • the beneficial agent is typically released into the aqueous solution in which the device is placed, although, as described in the literature, a catheter can be connected to the osmotic device so that the beneficial agent can be delivered to an aqueous environment remote from the site of the device (Amkraut, A., J.B. Eckenhoff, and K. Nichols, "Osmotic Delivery of Peptides and Macromolecules," Ad. Drug. Del. Rev. , 4[1990]255-276; Cuevas, P., A.M. Gonzales, F. Carceller, and A. Baird, Circ. Res., 69[1991]360-369).
  • Osmotic-delivery systems have been developed that release the beneficial agent either in a sustained manner via osmotic pumping or as a bolus via osmotic bursting (e.g., U.S. Patent Nos. 3,247,066, 3,952,741B1, 4,016,880, and 4,177,256). These delivery systems rely on semipermeable coatings to control the influx of water and to contain the beneficial agent within the core until it is released.
  • semipermeable coatings are either dense, microporous, or asymmetric in structure (e.g., U.S. Patent Nos. 3,845,770, 4,968,507, and European Patent Application 89308716.3, Publication No. 0357369).
  • the semipermeable membranes must be wetted by an aqueous solution to allow for release of the beneficial agent (Batt, B.C., "An Experimental Study of Osmotic Pumping by Highly Microporous Polymer Membranes," M.S. thesis, University of Kansas, 1982; U.S. Patent Nos. 4,968,507 and 4,340,054).
  • At least one delivery port must be formed in the semipermeable coating (e.g., by drilling or by forming pores in the coatings) for sustained delivery of a beneficial agent.
  • the beneficial agent can be released by bursting the coating as a result of hydrostatic pressure generated in the core by osmosis.
  • Osmotic devices have been described that have a combination of a hydrophilic semipermeable membrane covering a portion of the device and a hydrophobic porous membrane covering another portion of the device.
  • the pores (typically ⁇ 100 ⁇ m in diameter) of the hydrophobic-porous-membrane portion of the device contain hydrophobic liquids (e.g., oils), which inherently wet the hydrophobic membrane and are entrained therein.
  • Osmotic devices for lodgment in an aqueous environment in the interior of an animal have been described that utilize porous hydrophobic material to allow water inhibition while retaining non- volatile materials within the core (International Publication
  • porous hydrophobic material as the semipermeable membrane in osmotic devices has also been disclosed that use porous hydrophobic membranes for use in an aqueous environment (U.S. Patent Application Serial Number 08/096,144).
  • porous hydrophobic materials have been disclosed, their use in non-aqueous environments has not been contemplated.
  • Diffusional (i.e., non-osmotic) release of beneficial agents through pores in hydrophobic "nonsemipermeable" coatings has also been described in the literature (e.g., Junginger, H.E., and J.
  • Hydrophobic microporous films have also been used to release beneficial agents to non-aqueous environments at a controlled rate (U.S. Patent Nos. 3,770,199, 4,356,696, 4,915,301, and 4,605,165). Release from these devices is also by diffusion of the beneficial agent through the pores in the film.
  • hydrophobic microporous membranes are used in gas-transport/liquid-barrier applications. They have been used to selectively transport vapors and to act as barriers to liquids. Examples of such use are blood oxygenators, membrane-distillation processes, and breathable waterproof fabrics. Vapor- permeable coatings have also been used as selective and/or protective coatings on sensors or sorbents.
  • Sensor devices used to detect gases are commonly coated with a hydrophobic microporous film to prevent the electrode from becoming wetted.
  • ion-exchange resins have been coated with vapor-permeable coatings for the selective removal of ammonia. Methods to make vapor-permeable membranes and their application are described in several references (e.g., Kesting, R.E., "Synthetic Polymer Membranes,” 1985).
  • the semipermeable membranes described typically have low water permeability and thus require large surface area to achieve the desired flux and can also require long times before the membrane becomes wetted and consequently allows osmotic imbibition. Combination of an osmotic device that uses a vapor-permeable membrane and delivers the beneficial agent to a non-aqueous environment has not been previously disclosed.
  • This invention is directed to an osmotic device that, following the imbibition of water vapor, provides for the controlled release of a beneficial agent to a non-aqueous environment.
  • the device comprises a hydrophilic formulation containing an osmagent and a beneficial agent, surrounded by a container wall.
  • the wall of the container adjacent to the hydrophilic formulation is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0.1 ⁇ m and 30 ⁇ m.
  • the pores are substantially filled with a gas phase.
  • the hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa.
  • the wall of the container adjacent to the beneficial agent has at least one opening that allows the beneficial agent to be released.
  • the device In operation the device is placed in water or in an aqueous solution such that the semipermeable hydrophobic membrane is immersed and the opening for release of the beneficial agent is not immersed.
  • the beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibition of sufficient water vapor into the device core creating a hydrostatic pressure that forces the beneficial agent out of the device.
  • a flexible or movable barrier layer may be placed between the beneficial agent and the hydrophilic formulation to prevent mixing. This flexible or movable layer will also prevent contact between the water imbibed into the hydrophilic formulation and the beneficial agent.
  • water may be contained in the device, eliminating the need for an external water source. In this case, water would be contained in a sealed compartment adjacent to the semipermeable hydrophobic membrane. To initiate operation of the device, the seal between the water compartment and the semipermeable hydrophobic membrane would be broken, allowing water vapor to be imbibed through the hydrophobic membrane into the hydrophilic formulation.
  • hydrophobic microporous materials are compatible with common inexpensive container materials, allowing for ease in assembly and in forming seals with the container. Since the hydrophobic microporous material is selective only for water vapor, the hydrophilic formulation within the device will remain contained within the device.
  • Figure 1 is a diagram of an exemplary device of this invention where the hydrophilic formulation and beneficial agent are in adjacent layers.
  • Figure 2 is a diagram of an exemplary device of this invention where the hydrophobic formulation and the beneficial agent are separated by a movable piston-like barrier.
  • Figure 3 is a diagram of an exemplary device of this invention where the hydrophilic formulation and the beneficial agent are separated by a flexible barrier.
  • Figure 4 is a diagram of an exemplary device of this invention where the hydrophilic formulation and the beneficial agent are in adjacent layers and a water reservoir with a breakable seal is included in the device.
  • Figure 5 is a diagram of an exemplary device of this invention where the hydrophobic microporous material is in the form of a tube and a movable piston separates the hydrophilic formulation and the beneficial agent.
  • the devices of this invention operate by imbibing water into the device through a microporous hydrophobic semipermeable membrane. This imbibition of water creates a hydrostatic pressure within the device causing the beneficial agent to be pumped out of the device into a non-aqueous environment.
  • non-aqueous environment we mean that the beneficial agent would be released into an environment that does not consist of liquid water and is not any cavity or portion of animals or man.
  • Water for imbibition must be provided in an external reservoir or included in a separate compartment within the device.
  • Water in an external reservoir could be utilized by placing the device in the water such that the hydrophobic membrane is immersed in the water and the opening for delivery of beneficial agent is out of the water.
  • devices similar to those shown in Figures 1, 2, and 3 could sit in water such that the hydrophobic membrane was toward the bottom of the container and the emanator pad is out of the water.
  • imbibition of water could be used to pump fragrance out onto the emanator pad, providing constant release of the fragrance mixture, which then evaporates from the emanator pad into the air.
  • Water reservoirs could also be moist soil, or bodies of water such as a stream, river, pond, lake, or ocean.
  • the device In each case, the device must be positioned so that the hydrophobic membrane is immersed in the water reservoir and the delivery port for beneficial agent is out of the water reservoir and in a non-aqueous environment.
  • Water reservoirs could also be moisture in the air.
  • the hydrophilic formulation could imbibe water from the air through microporous hydrophobic materials to generate the pressure necessary to osmotically pump beneficial agent out of the device.
  • Water could also be contained within a sealed compartment of the device. To operate in this manner, a seal between the water compartment and the hydrophobic membrane must be ruptured or otherwise caused to open. This could be accomplished, for example, by puncturing or ripping the seal. Water would then be imbibed from the water reservoir through the hydrophobic membrane into the hydrophilic formulation. As described above, this imbibition of water would force the beneficial agent out of the delivery opening into a non-aqueous environment.
  • water vapor is imbibed into the hydrophilic formulation from the aqueous solution through the pores in the membrane due to osmosis (liquid water is excluded by the hydrophobicity of the membrane; liquid water will not wet the pores of the membrane).
  • osmosis liquid water is excluded by the hydrophobicity of the membrane; liquid water will not wet the pores of the membrane.
  • a hydrostatic pressure is developed within the compartment containing the hydrophilic formulation.
  • the hydrostatic pressure in this compartment causes the beneficial agent to be released through the opening to the environment of use in a sustained manner by an osmotic-pumping mechanism.
  • the hydrostatic pressure can cause the outlet for the beneficial agent to burst open, releasing the beneficial agent.
  • any semipermeable hydrophobic microporous membrane that is solid under the conditions of use, is permeable to water vapor, and the pores of which are substantially filled with a gas phase and are not wetted by the aqueous medium in contact with the semipermeable hydrophobic membrane may be used in this invention.
  • aqueous medium is meant a composition containing water as an available liquid component (e.g., solutions of organic or inorganic substances particularly electrolytes, and mixtures of substances in water, e.g., moist soil).
  • substantially filled with a gas phase is meant that most of the pores do not contain solids or liquids that block the pores, but contain gases such as air, oxygen, nitrogen, or water vapor.
  • the hydrophobic membrane has pores having an average pore size between about 0.1 ⁇ m and 30 ⁇ m preferably less than 10 ⁇ m and the hydrophobic membrane is impermeable to water at a pressure less than about 100 Pa, and preferably less than 100,000 Pa.
  • the hydrophobic membrane has a water- vapor transmission rate greater than 2 g-mm m -24 hour, a contact angle with water greater than 50 degrees, and a total pore volume of between 5% and 95%.
  • the membrane material itself in the nonporous state is substantially impermeable to the hydrophilic formulation (i.e., the hydrophilic formulation will not diffuse through the membrane material to an appreciable extent).
  • substantially impermeable is meant less than 1% of the formulation is released through the membrane material over a 24-hour period.
  • the membrane material in the nonporous state
  • the membrane thickness may be any dimension that provides appropriate water inhibition and structural stability, the membrane is preferably 5 ⁇ m to 2 cm in thickness. The pores in the membrane must create at least one continuous pathway through the membrane thickness.
  • the membrane may be combined with another type of impermeable wall portion to totally surround the hydrophilic formulation and beneficial agent.
  • the membrane is polymeric or a wax, although appropriately treated inorganic materials such as ceramics, metals, or glasses may be used.
  • the polymer's molecular weight should be of such a size that the polymer is solid at the temperature of use and appropriate for the application (e.g., durable for handling purposes).
  • Polysulfones polyethersulfones, polytetrafluoroethylene, polyvinyl chloride, polyacrylonitrile, polyvinylidene chloride, polyvinylidene fluoride, polyimides, polycarbonates, polyurethanes, polyvinyl acetates, polyamides, polysiloxanes, polyesters.
  • Polyalkenes such as polyethylene, ethylene vinyl alcohol copolymer, polypropylene, poly(l,2-dimethyl-l-butenylene), poly(l-bromo-l-butenylene), poly(l,butene), poly(l- chloro-1-butenylene), poly(l-decyl-l-butenylene), poly(l-hexane), poly(l-isopropyl-l- butenylene), poly(l-pentene), poly(3-vinylpyrene), poly(4-methoxy-l-butenylene); poly(ethylene-co-methyl styrene), polyvinyl chloride, poly(ethylene-cotetrafluoroethylene), poly(ethylene-terephthalate), poly(dodecafluorobutoxylethylene), poly(hexafluoroprolylene), poly(hexyloxyethylene), poly(isobutene), poly(isobutene-coisoprene), poly(
  • Polystyrenes such as poly(2,4-dimethyl styrene), poly(3-methyl styrene), poly(4- methoxystyrene), poly(4-methoxystyrene-stat-styrene), poly(4-methyl styrene), poly(isopentyl styrene), poly(isopropyl styrene).
  • Polyvinyl esters or polyvinyl ethers such as poly(benzoylethylene), poly(butoxyethylene), poly(chloroprene), poly(cyclohexyloxyethylene), poly(decyloxyethylene), poly(dichloroethylene), poly(difluoroethylene), poly(vinyl acetate), poly(vinyltrimethylstyrene).
  • Polyacrylic acid derivatives such as polyacrylates, polymethyl methacrylate, polyethyl methacrylate, poly(acrylic acid) higher alkyl esters, poly(hexadecyl methacrylate- co-methylmethacrylate), poly(methylacrylate-co-styrene), poly(n-butyl methacrylate), poly(n-butyl-acrylate), poly(cyclododecylacrylate), poly(benzylacrylate), poly(butylacrylate), poly(secbutylacrylate), poly(hexyl acrylate), poly(octylacrylate), poly(decylacrylate), poly(dodecylacrylate), poly(2-methyl-butylacrylate), poly(adamantyl methacrylate), poly(benzyl methacrylate), poly(butyl methacrylate), poly(2-ethylhexyl methacrylate), poly(octyl methacrylate), acrylic resins.
  • Polyethers such as poly(octyloxyethylene), poly(oxyphenylethylene), poly(oxypropylene), poly(pentyloxyethylene), poly(phenoxy styrene), poly(secbutoxylethylene), poly(tert-butoxyethylene).
  • Exemplary natural and synthetic waxes useful as the hydrophobic membrane include: insect and animal waxes such as Chinese insect wax, spermaceti, fats and wool wax; vegetable waxes such as bamboo leaf wax, candelilla wax, carnauba wax, Japan wax, ouricury wax, Jojoba wax, bayberry wax, Douglas-fir wax, cotton wax, cranberry wax, capeberry wax, rice-bran wax, castor wax, Indian corn wax, hydrogenated vegetable oils (e.g., castor, palm, cottonseed, soybean), sorghum grain wax, Madagascar wax, orange peel wax, shellac wax, sisal hemp wax, and rice wax; mineral waxes such as Montan wax, peat waxes, petroleum wax, petroleum ceresin, ozokerite wax, microcrystalline wax, and paraffins; and synthetic waxes such as polyethylene wax, Fischer-Tropsch wax, chemically modified hydrocarbon waxes and cetyl esters wax.
  • Especially preferred membrane materials include polyethylene, polypropylene,
  • the semipermeable hydrophobic membrane covers at least a portion of the hydrophilic formulation which must contain an osmagent.
  • the osmagent may be any material that causes the osmotic pressure of the hydrophilic formulation to be greater than that of the aqueous medium.
  • the hydrophilic formulation must have an effective osmotic pressure greater than that of the surrounding aqueous medium so that there is a net driving force for water vapor to enter the device.
  • the higher osmotic pressure within the hydrophilic formulation allows the hydrostatic pressure in the device to increase to achieve either the desired osmotic pumping or bursting causing release of the beneficial agent.
  • the osmagent can be either soluble or swellable.
  • Osmotically effective solutes are inorganic and organic salts and sugars.
  • Osmotically effective compounds may be used singly or in combination and include, for example, magnesium sulfate, magnesium chloride, sodium chloride, lithium chloride, potassium sulfate, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, calcium carbonate, sodium sulfate, calcium sulfate, potassium acid phosphate, calcium lactate, d-mannitol, urea, inositol, magnesium succinate, tartaric acid, water soluble acids, alcohols, surfactants, and carbohydrates such as sugars (e.g., raffinose, sucrose, glucose, lactose, fructose), sugar derivatives, algin, sodium alginate, potassium alginate, carrageenan, fucoridan, furcellaran, laminaran, hypnea, gum arabic, gum ghatti, gum karaya, loc
  • a water-swellable component such as a hydrogel is used.
  • the swellable excipient aids in forcing open a delivery port for release of beneficial agent as a result of the imbibition of water vapor into the device.
  • hydrogels include polyacrylic acid derivatives (e.g., polyacrylates, poly(acrylic acid) higher alkyl esters, polyacrylamides, ⁇ oly(hydroxy ethyl methacrylate), poly( vinyl alcohol), poly(ethylene oxide), poly(N-vinyl-2-pyrrolidone), naturally occurring resins such as polysaccharides (e.g., dextrans, water-soluble gums, starches, and chemically modified starches), cellulose derivatives (e.g., cellulose esters, cellulose ethers, chemically modified cellulose, microcrystalline cellulose, sodium carboxymethylcellulose, and methylcellulose).
  • Preferred hydrogels include ethylene oxide derivatives such as polyethylene oxide
  • PEO polyethylene glycol
  • Other preferred hydrogels are starches, gums, crosslinked hydrogels, and carboxymethylcellulose.
  • the hydrogel employed can be a blend of, for example, two or more polymers.
  • different hydrogels comprising blends of PEO polymers of different molecular weights can be prepared and employed. Such blends can be adjusted to assist in achieving the desired delivery rates for the beneficial agents.
  • the beneficial agents used in the devices of this invention include for example, any active substance that produces a desired effect in the non-aqueous environment of use.
  • active substances include inorganic and organic compounds such as agrichemicals, including insecticides, herbicides, fertilizers, fungicides, pheromones, algaecides, insect growth regulators, and plant growth regulators; reaction catalysts; reaction feedstocks; pH-controlling agents; enzymes, enzyme inhibitors; disinfectants: odor absorbants; flavors; and fragrances.
  • agrichemicals including insecticides, herbicides, fertilizers, fungicides, pheromones, algaecides, insect growth regulators, and plant growth regulators
  • reaction catalysts including insecticides, herbicides, fertilizers, fungicides, pheromones, algaecides, insect growth regulators, and plant growth regulators; reaction catalysts; reaction feedstocks; pH-controlling agents; enzymes, enzyme inhibitors; disinfectants: odor absorbants; flavors; and fragrances.
  • the release profile can be tailored so that the release duration is from instanteous (i.e., bursting) to longer than several months.
  • a device containing a hydrophilic formulation with a water-swellable hydrogel designed to expand and burst open a film containing the beneficial agent has a very short release duration-essentially as fast as the beneficial agent could evaporate or otherwise disperse.
  • a device in which the beneficial agent is released by osmotic pumping can have a much longer release duration.
  • release of beneficial agent can be initiated by bursting open a constrained opening, and then release could continue over a long time by osmotic pumping.
  • the release profile of the devices of this invention can also be advantageously tailored by altering time lags between exposure of the device to the aqueous solution and release of the beneficial agent.
  • the membrane pores, membrane composition, and membrane thickness are of a number, composition, and size sufficient to provide the desired time lag.
  • Preferred devices include those schematically shown in Figures 1-5, and described generally below. Particularly preferred devices include those having a hydrophobic semipermeable membrane of polyethylene, polypropylene, or polyvinylidene fluoride. It is especially preferred that the hydrophilic formulation contains an osmagent that is a sugar or a salt. Particularly preferred is when the hydrophilic formulation has a surface tension of about 60-70 dyn/cm.
  • the shape and dimensions of the dispensing device can vary based on the particular application.
  • the device may be formed in a shape that is aesthetically pleasing. It is especially preferred that the device resemble a flower or natural plant for releasing a fragrance.
  • the dispensing-device dimensions may also vary with the quantity of beneficial agent that must be delivered.
  • the device will contain 0.1 to 400 grams of fragrance and 1 to 100 grams of hydrophilic formulation.
  • agrichemicals, chemical reactions, flavors, and fragrances shapes and sizes will be determined by the method of use and may be different from those listed above.
  • the beneficial agent 3 and the hydrophilic formulation 2 are formed in layers inside a container made of walls 5 that are impermeable to both the beneficial agent 3 and the hydrophilic formulation 2.
  • the hydrophilic formulation 2 is next to the porous hydrophobic semipermeable membrane 1.
  • the device is placed in water so that the hydrophobic membrane 1 is immersed in water and the delivery port 4 and emanator pad 6 are out of the water and exposed to the non-aqueous environment. .
  • Water is imbibed into the hydrophilic formulation 2 through the hydrophobic membrane 1.
  • the increase in volume due to water imbibition creates a hydrostatic pressure that forces the beneficial agent 3 out of the delivery port 4 and onto the emanator pad 6, where it is available to the desired environment.
  • the device shown in Figure 2 is similar to the device in Figure 1 with the addition of a movable piston-like barrier 7 between the hydrophilic formulation 2 and the beneficial agent 3.
  • a movable piston-like barrier 7 between the hydrophilic formulation 2 and the beneficial agent 3.
  • the hydrostatic pressure created forces the movable barrier 7 toward the delivery port 4 and forces the beneficial agent 3 out the delivery port 4.
  • the movable barrier prevents contact between the hydrophilic formulation and beneficial agent.
  • the device in Figure 3 is similar to the device in Figure 2 except that the movable piston-like barrier 7 has been replaced with a flexible barrier film 8.
  • This flexible barrier film 8 collapses as water is imbibed into the hydrophilic formulation 2, which causes the beneficial agent 3 to be delivered.
  • Figure 4 is similar to Figure 1 with the addition of a water reservoir 9 within the device.
  • a water reservoir could be added to the devices shown in Figures 2 and 3.
  • the hydrophilic formulation could be in a small tube that moves a larger-diameter piston that pumps out beneficial agent.
  • a breakable seal 10 is placed between the water reservoir 9 and the porous hydrophobic semipermeable membrane 1. This prevents water imbibition into the hydrophilic formulation during storage.
  • the breakable seal 10 must be ruptured or opened. This could be accomplished in a number of ways, such as by twisting the device and ripping the seal or by puncturing the seal. Once the seal is ruptured, water can then be imbibed into the hydrophilic formulation, causing release of the beneficial agents.
  • the hydrophobic microporous material is formed as a tube 1.
  • the movable piston 7 is forced up pumping the beneficial agent 3 to the emanator pad 6.
  • the surface area of the hydrophobic microporous material 1 increases.
  • the water flux increases proportionally to the increase in surface area.
  • the rate of release of beneficial agent from these devices is governed mostly by the surface area, thickness, and porosity of the hydrophobic microporous semipermeable membrane and the osmotic driving force across the hydrophobic membrane.
  • the osmotic driving force is the difference in osmotic pressure between the hydrophilic formulation and the water reservoir. As the osmotic driving force increases, the water imbibition rate increases proportionately. Thus, hydrophilic formulations that contain osmagents with higher osmotic pressures will have higher water-imbibition rates and consequently higher release rates.
  • Flux of water through the porous hydrophobic membrane is proportional to the porosity and inversely proportional to the thickness of the material. The greater the porosity, the easier the water vapor can move through the membrane. Thus, water flux increases as porosity increases. As material thickness is made thinner the water vapor has a shorter distance to move through the pores and consequently the water flux increases. Thus, -14-
  • the water flux through the hydrophobic membrane is proportional to the surface area of membrane.
  • the rate of release can be controlled by controlling the surface area.
  • a device could be made such that an opening exposing the hydrophobic membrane to water could be closed or opened to varying degrees to allow adjustment of the release rate during use.
  • the opening could be formed in the seal between the water reservoir and the hydrophobic membrane, which in the closed position would provide the barrier desired for storage and then could be opened to the desired degree allowing the release rate to be controlled during use.
  • the rate of release could be either increased or decreased with time by having the surface area change.
  • the devices of this invention may be made using the above-described materials using the following processes and other conventional methods.
  • Microporous coatings can be made by a variety of methods, such as phase inversion, scintering, leaching, and irradiation. All of these methods for forming hydrophobic micropores films have been described in the literature, especially for use as membranes for separations (Synthetic Polymer Membranes, by R.E. Resting, John Wiley & Sons, 1985).
  • phase-inversion methods such as the vapor-quench process, the dry process, the liquid-quench process, and the thermal process, can be used to form microporous coatings.
  • Commercially available microporous films or microporous hollow fibers or tubes or other geometries can be used in this invention and can be used as part of the container.
  • membrane formation is accomplished by penetration of a precipitant for the polymer into the solution film from the vapor phase, which may be saturated with the solvent used.
  • a porous membrane is produced without a skin and with an even distribution of pores over the membrane thickness.
  • the polymer In the dry process, the polymer is dissolved in a mixture of a solvent and a poor solvent, of which the solvent is more volatile. The polymer precipitates when the mixture shifts in composition during evaporation to a higher nonsolvent content. A skinned or nonskinned microporous membrane can be the result.
  • film formation is caused by the immersion of a film or coating or polymer solution into a nonsolvent bath. The polymer precipitates as a result of solvent loss and nonsolvent penetration (exchange of the solvent with nonsolvent).
  • a skinned or nonskinned membrane can be the result.
  • a solution of polymer in a latent solvent is brought to phase separation by a cooling step. When evaporation of the solvent is prevented, the membrane typically will be porous.
  • Microporous coatings can also be made by inclusion of a leachable component in the coating formulation.
  • a leachable component for example, small particles of sugar, salt, or water-soluble materials equal to the desired pore size can be suspended or dissolved in the coating solution. Once the coating is applied, the water-soluble materials can be leached out by immersion in water, forming a microporous structure.
  • the small particles can consist of volatile solids such as menthol, naphthalene, camphor, phenol, ammonium acetate, or ammonium carbonate.
  • Microporous hydrophobic films have also been made by scintering particles of hydrophobic polymers or ceramic or metals together under heat and pressure. Microporous hydrophobic films are also commonly made by irradiation.
  • Porous hydrophobic membranes/materials are readily available from a number of suppliers. For example, flat films and sheets are available from AKZO (Wuppertal, Germany); Hoechst Celanese (Charlotte, NC); Millipore (Befford, MA); and W.L. Gore & Associates, Inc. (Elkton, MD). Scintered porous hydrophobic materials are available from companies such as Purex (Fairburn, GA), and Interflow Technologies (Brooklyn, NY). In addition, porous hydrophobic hollow fibers and tubes are available from companies such as AKZO, Hoechst Celanese, and AquaAir, Inc. (Bend, OR).
  • Flat-sheet microporous films can be sealed together, forming pouches that contain hydrophilic formulations and beneficial agents.
  • the flat-sheet microporous film can also be sealed over the opening of an impermeable container.
  • hollow fibers having microporous walls can be used with their ends sealed, enclosing the hydrophilic formulation and the beneficial agent within the lumen of the fiber.
  • Methods for using the devices of this invention include placing these devices in home, office, or other living space.
  • Devices of this invention can also be used to deliver agents to such environments of use as backyards, greenhouses, or agricultural fields by placing devices in moist soil or in water. In such cases, the devices are placed into the soil or water such that the hydrophobic membrane is immersed and such that the delivery port for release of beneficial agent is in the air.
  • such devices could be used to deliver beneficial agent to air-supply systems, such as heating, cooling, oxygenation, or filtered air.
  • Example 1 Osmotic Water Flux Through Hydrophobic Microporous Films Devices were made to measure the water flux through hydrophobic microporous films by sealing the films to one end of a length of polyethylene tubing.
  • Polyethylene tubing (inner diameter of 1/2 inch) was cut to about 15 cm long and one end was heated by placing the tubing on end onto a hot plate. The tubing was heated until the polymer at the end of the tubing was visibly melted. The tubing was then removed from the hot plate and pressed onto the hydrophobic microporous films, bonding the films to the melted end of the tubing.
  • the tubing with one end sealed by the hydrophobic film was filled to a level of about 9 cm with a saturated solution of sodium chloride with excess solids in water.
  • the sealed tubes were placed in a water reservoir (beakers of water).
  • the water level in the beaker was lower than the water level in the tubing so that any hydrostatic pressure would cause the solution in the tubing to go through the film at the bottom of the tube and into the water in the beaker if there were leaks in the tubing.
  • Water flux was measured by weight gain on the sealed tube, and salt flux into the beaker of water was measured by measuring the conductivity of the water in the beaker. The tests were continued until the water level in the tubes rose to the top of the tubing and overflowed.
  • Porous polypropylene tubes (from Akzo, Nobel, Wuppertal, Germany) were obtained that had an inner diameter of 0.5 cm and and outer diameter of 0.9 cm.
  • the tubes were cut to about 15 cm in length and sealed at one end with a dense film of polytetrafluoroethylene (glued with hot-melt adhesive).
  • the tubing was filled with a slurry of sodium chloride to a level of about 9 cm from the bottom (about 2 ml). To measure water flux, these tubes were placed into a water reservoir.
  • the water in the reservoir was slightly less than 9 cm deep so that if there were leaks in the tubes, water would flow out of the tubes and into the water reservoir due to the difference in hydrostatic pressure.
  • Water flux was measured by weight gain of the tubes. The tests were continued until the water. level rose in the tubes to the top of the tubes and overflowed. The water flux normalized for surface area was 0.1 g/cm 2 -day.
  • the salt concentration in the water reservoir was also measured (by conductivity) to detect salt diffusing out of the tubes into the water reservoir. In all tests no salt was detected in the water reservoir, indicating that the water was imbibed into the tubes by osmosis through the pores in the hydrophobic microporous tubing material.)
  • Example 3 Release Rates of Fragrance Dependent on the Osmotic Driving Force Devices similar to those described in Example 1 were made to demonstrate osmotically driven release of a fragrance. Tubes were made that were sealed with porous polypropylene films (Accurel, PP type ZE, Akzo Nobel, Wuppertal, Germany). The tubes were filled with various slurries of osmagent as listed in Table II. On top of the water/osmagent slurries was placed a fragrance oil that was immiscible with the aqueous slurry.
  • the top of the tube was sealed with an emanator pad (the emanator pad consisted of thick filter paper 2.1 cm in diameter) to spread the fragrance out, increasing the surface area and allowing the fragrance to evaporate into the air.
  • the fragrance-containing tubes were placed into beakers of water to initiate release. Due to osmotic imbibition of water into the osmagent slurry, the fragrance was pumped to the emanator pad, where it evaporated into the air.
  • the fragrance release rates were measured and are listed in Table II. As shown, the release rates are proportional to the osmotic driving force across the hydrophobic microporous film. Without an osmagent the release of fragrance was much lower, as expected for a device that is not osmotically pumping the fragrance to the emanator pad. Table II. Release Rates of Fragrance Dependent on Osmagent
  • Devices were made as described in Example 3 except that the tubing diameter was different. Devices were made that had inner diameters of either 1/2 or 1/4 inch. The surface area of the hydrophobic microporous film attached to the end of the tubing was 0.8 cm 2 for the 1/2 inch tubing and 0.2 cm 2 for the 1/4 inch tubing. In each of the devices a slurry of sodium chloride was used as the osmagent. The devices were placed in water and monitored to determine the release rate of the fragrance. Fragrance release rates were
  • fragrance having 0.2 cm of surface area.
  • the release rate of fragrance was proportional to the surface area of the hydrophobic microporous film, indicating that the release of fragrance was controlled by the osmotic imbibition of water into the device, which then pumped the fragrance out to the emanator pad.
  • Example 5 Release of Insect Pheromone From Osmotic Device Using a Porous Hydrophobic Film Devices were made as described in Example 3 except that instead of loading the device with a fragrance oil, the devices were loaded with an insect pheromone (E-4- tridecenyl aetate) that is used to disrupt mating of the tomato pinworm.
  • E-4- tridecenyl aetate insect pheromone
  • Two types of devices were made: one contained sodium chloride as the osmagent and the other did not contain an osmagent. The devices were placed in moist soil and the release rates measured. The release rate from the device containing sodium chloride as the osmagent was 720 mg/cm 2 -day, whereas without an osmagent the release rate was less than 1 mg/cm 2 -day.
  • osmagent used in these devices was a slurry of sodium chloride.
  • the fragrance-containing dispensers were suspended in air maintained at 100% RH at room temperature. Osmotic imbibition of water from the air through the hydrophobic microporous membrane and into the hydrophilic formulation forced the fragrance oil to the top of the tube where it could be released.
  • the water flux into these devices was measured to determine the rate of osmotic imbibition (this rate of osmotic imbibition could be translated to release of fragrance since imbibition of water results in equivalent volumes of fragrance pumped out of the device).
  • the water flux into the devices was about 0.1 g/cm 2 -day indicating that about 85 mg/day of
  • fragrance could be delivered from a device having a membrane area of 1 cm and placed in air at 100% RH.
  • the devices as described can be used to dispense a number of benificial materials such as fragrance, insecticide, herbicide, fungicide, pheromone or food source to a non- aqueous environment such as the atmosphere.
  • benificial materials such as fragrance, insecticide, herbicide, fungicide, pheromone or food source

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne un dispositif osmotique qui, à la suite d'une imbibition de vapeur d'eau, assure la libération maîtrisée d'un agent utile (37) dans un environnement non aqueux. Ledit dispositif comporte une formulation hydrophile (2) et un agent utile, entourés par une paroi (5). Cette paroi est constituée au moins en partie d'une membrane microporeuse hydrophobe semi-perméable (1) dont la taille moyenne des pores est comprise entre 0,1 νm et 30 νm. Les pores sont pratiquement remplis d'un élément en phase gazeuse. La membrane hydrophobe est perméable à l'eau dans la phase vapeur et elle est imperméable à un milieu aqueux à une pression inférieure à 100 Pa environ. L'agent utile est libéré, par exemple, par pompage osmotique ou par éclatement osmotique lors de l'imbibition de vapeur d'eau en quantité suffisante à l'intérieur de la formulation hydrophile. Les flux élevés d'eau associés à ces membranes hydrophobes perméables à la vapeur facilitent la livraison de grandes quantités d'agents utiles sans qu'il soit nécessaire de disposer de grandes aires de surface ( ou quantités) de membrane microporeuse hydrophobe. En outre, l'utilisation de membranes microporeuses hydrophobes semi-perméables rend possible l'utilisation de ces dispositifs osmotiques dans des environnements à disponibilité aqueuse limitée, tels que l'air ou le sol.
PCT/US1996/009728 1995-06-13 1996-06-10 Dispositifs de liberation osmotique recouverts d'une couche mince impermeable a la vapeur WO1996041621A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61070/96A AU6107096A (en) 1995-06-13 1996-06-10 Osmotic-delivery devices having vapor-permeable coatings

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/489,888 US5798119A (en) 1995-06-13 1995-06-13 Osmotic-delivery devices having vapor-permeable coatings
US08/489,888 1995-06-13

Publications (2)

Publication Number Publication Date
WO1996041621A2 true WO1996041621A2 (fr) 1996-12-27
WO1996041621A3 WO1996041621A3 (fr) 1997-03-27

Family

ID=23945694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009728 WO1996041621A2 (fr) 1995-06-13 1996-06-10 Dispositifs de liberation osmotique recouverts d'une couche mince impermeable a la vapeur

Country Status (5)

Country Link
US (1) US5798119A (fr)
AR (1) AR002473A1 (fr)
AU (1) AU6107096A (fr)
WO (1) WO1996041621A2 (fr)
ZA (1) ZA965030B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037959A3 (fr) * 1997-02-24 1998-11-12 Willuweit Thomas Dispositif de distribution dosee de substances
WO2000023663A1 (fr) 1998-10-21 2000-04-27 Reckitt Benckiser (Uk) Limited Distributeur

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030358A (en) * 1997-08-08 2000-02-29 Odland; Rick Matthew Microcatheter and method for site specific therapy
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US6632217B2 (en) * 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US7435241B1 (en) * 2001-11-17 2008-10-14 Dascanio Gustavo A Fluid dispenser closure including tube having hydrophilic and hydrophobic portions
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
JP2007516948A (ja) * 2003-07-19 2007-06-28 ワード，ウォレン 液体不透過性であるが気体透過性の層で被覆した成分を具える組成物、皮膚およびその他の外分泌腺疾病の治療へのこの組成物の使用
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
DE102004042578A1 (de) * 2004-09-02 2006-03-23 Roche Diagnostics Gmbh Mikropumpe zur Förderung von Flüssigkeiten mit niedrigen Förderraten im Druck/Saug-Betrieb
US8063221B2 (en) 2006-03-13 2011-11-22 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
KR20090101362A (ko) 2006-12-26 2009-09-25 파마시클릭스, 인코포레이티드 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
HUE031070T2 (en) 2007-03-15 2017-06-28 Auspex Pharmaceuticals Inc Deuterated d9-venlafaxine
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US8389514B2 (en) * 2007-09-11 2013-03-05 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
KR101597841B1 (ko) 2007-09-12 2016-02-26 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
CA2972138A1 (fr) 2008-03-17 2009-09-24 Ambit Biosciences Corporation Composes modulateurs de raf kinase et methodes d'utilisation associees
JP2012501233A (ja) * 2008-08-28 2012-01-19 ミクロリン・エルエルシー 有益薬剤を一定速度で送出するための装置および方法
WO2010081077A2 (fr) * 2009-01-09 2010-07-15 Massachusetts Institute Of Technology Filtration de liquide en utilisant une différence de pression sur une membrane hydrophobe
WO2010088450A2 (fr) 2009-01-30 2010-08-05 Celladon Corporation Procédés de traitement de maladies associées à la modulation de serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
HRP20140174T1 (hr) * 2009-02-27 2014-04-25 Ambit Biosciences Corporation Derivati kinazolina kao modulatori jak-kinaze i postupci njihove upotrebe
WO2010101967A2 (fr) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase
CA2754909A1 (fr) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combinaison d'une indazolylaminopyrrolotriazine et d'un taxane pour un traitement du cancer
AU2010221990B2 (en) * 2009-03-11 2015-06-04 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
WO2010110686A1 (fr) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation en thérapie anticancéreuse
RU2011143359A (ru) 2009-03-27 2013-05-10 Патвэй Терапьютикс, Инк. Примидинил- и 1,3,5-триазинилбензимидазолсульфонамиды и их применение в терапии рака
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2421829B1 (fr) 2009-04-22 2015-09-30 Axikin Pharmaceuticals, Inc. Antagonistes ccr3 d'arylsulfonamides 2,5-disubstitués
KR20120013403A (ko) 2009-04-22 2012-02-14 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
CA2758729A1 (fr) 2009-04-22 2010-10-28 Axikin Pharmaceuticals, Inc. Antagonistes ccr3 d'arylsulfonamides
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
TW201105662A (en) 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DK2451435T4 (da) 2009-07-08 2022-02-28 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (fr) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
CA2784748A1 (fr) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c a base de 5,5-arylene ou heteroarylene condense
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (fr) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Sels d'indazolylpyrrolotriazine
CN102892754A (zh) 2010-03-17 2013-01-23 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
EP2576513A1 (fr) 2010-06-01 2013-04-10 Biotheryx Inc. Dérivés d'hydroxypyridone, compositions pharmaceutiques réalisées à partir de ces dérivés, et utilisations thérapeutiques correspondants pour traiter des maladies prolifératives
WO2011153199A1 (fr) 2010-06-01 2011-12-08 Biotheryx, Inc. Méthodes permettant de traiter des tumeurs malignes hématologiques au moyen de 6-cyclohexyl-1-hydroxy-4-méthyl-2(1h)-pyridone
CN103108868B (zh) 2010-06-07 2015-11-25 诺沃梅迪科斯有限公司 呋喃基化合物及其用途
CN101987083B (zh) * 2010-07-16 2012-12-12 钟术光 一种控释制剂特别是零级释放的控释制剂制备方法
CN102018962B (zh) * 2010-07-16 2013-11-06 钟术光 在控释制剂中的聚合物增强剂
NZ605860A (en) 2010-07-19 2015-04-24 Summa Health System Use of vitamin c, and chromium-free vitamin k or 2-methyl-1,4-naphthalendione, and compositions thereof for treating a polycystic disease
EP2611809A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Composés d'azolopyridine et d'azolopyrimidine et méthodes d'utilisation associées
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
AU2011296074B2 (en) 2010-09-01 2015-06-18 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611448A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 7-cyclylquinazoline et leurs méthodes d'utilisation
EP2611502A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Composés de modulation du récepteur a3 de l'adénosine et leurs méthodes d'utilisation
ES2619850T3 (es) 2010-09-01 2017-06-27 Ambit Biosciences Corporation Sales de hidrobromuro de una pirazolilaminoquinazolina
EP2663553B1 (fr) 2010-09-01 2015-08-26 Ambit Biosciences Corporation Composés quinoléine et isoquinoléine en tant que modulateurs de jak
MX2013002384A (es) 2010-09-01 2013-07-05 Ambit Biosciences Corp Compuestos quinazolina y metodos para utilizarlos.
WO2012030894A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés thiénopyridines et thiénopyrimidines et leurs procédés d'utilisation
EP2611794A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 4-azolylaminoquinazoline et leurs méthodes d'utilisation
WO2012044641A1 (fr) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinylbenzimidazolsulfonamides et leur utilisation en thérapie anticancéreuse
CN103298786B (zh) 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
EP2481411A1 (fr) 2011-01-27 2012-08-01 Ratiopharm GmbH Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135175A1 (fr) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (cycloalkylamino ou hétérocyclylamino alpha-substitué) pyrimidinyl et 1,3,5-triazinyl benzimidazoles, compositions pharmaceutiques les contenant et leur utilisation dans le traitement des maladies prolifératives
MX345238B (es) 2011-03-28 2017-01-23 Mei Pharma Inc (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
JP6134376B2 (ja) 2012-03-16 2017-05-24 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
CA2879603A1 (fr) 2012-07-27 2014-01-30 Ratiopharm Gmbh Formes galeniques orales destinees a une liberation modifiee comprenant du ruxolitinib
CA2881129A1 (fr) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Antagonistes de ccr3 de type arylsulfonamides enrichis en isotopes
WO2014055647A1 (fr) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl et sulfonyl benzimidazolyl) pyrimidines et triazines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter les maladies prolifératives
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
US9156781B2 (en) 2012-11-30 2015-10-13 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
CA2897665A1 (fr) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamines c et k pour le traitement de maladies polykystiques
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (fr) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
EP3114122A1 (fr) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci
WO2015143161A1 (fr) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Dérivés de benzimidazole en tant qu'inhibiteurs de la tyrosine kinase erbb pour le traitement du cancer
KR20240064750A (ko) 2014-03-20 2024-05-13 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
PL3272338T3 (pl) 2014-04-17 2021-01-11 Develco Pharma Schweiz Ag Doustna postać dawkowania ketaminy
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
UA118312C2 (uk) 2014-12-23 2018-12-26 Ексікін Фармасутікалз, Інк. 3,5-діамінопіразолові інгібітори кінази
MY189806A (en) 2015-06-23 2022-03-08 Neurocrine Biosciences Inc Vmat2 inhibitors for treating neurological diseases or disorders
HRP20210469T1 (hr) 2015-10-30 2021-05-14 Neurocrine Biosciences, Inc. Valbenazin ditosilat i njegovi polimorfi
HRP20220621T1 (hr) 2015-12-23 2022-06-24 Neurocrine Biosciences, Inc. Postupak sinteze za proizvodnju (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
CA3020681A1 (fr) 2016-04-11 2017-10-19 Clexio Biosciences Ltd. Derives de ketamine deuteres
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combination therapy
CN110087657A (zh) 2016-09-28 2019-08-02 阿托莎遗传股份有限公司 过继细胞治疗的方法
CA3042055A1 (fr) 2016-11-09 2018-05-17 Novomedix, Llc Sels de nitrite de 1,1-dimethylbiguanide, compositions pharmaceutiques et methodes d'utilisation
EP4400171A3 (fr) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la schizophrénie ou du trouble schizophafficeux
CA3051834C (fr) 2017-01-27 2024-05-28 Neurocrine Bioscienes, Inc. Procedes d'administration de certains inhibiteurs de vmat2
WO2018164996A1 (fr) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Posologie pour la valbénazine
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (fr) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la dyskinésie induite par la lévodopa
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
WO2018234568A2 (fr) 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorkétamine destinée à être utilisée dans le traitement de la dépression
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
WO2019139869A1 (fr) 2018-01-10 2019-07-18 Cura Therapeutics Llc Compositions pharmaceutiques comprenant des phénylsulfonamides, et leurs applications thérapeutiques
MA52896A (fr) 2018-06-14 2021-04-21 Neurocrine Biosciences Inc Composés inhibiteurs de vmat2, compositions et méthodes associées
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US20220274922A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
US20220274921A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
TWI862642B (zh) 2019-07-26 2024-11-21 美商艾斯佩維他治療學公司 官能化的長鏈烴一元及二元羧酸及其用於預防或治療疾病的用途
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2021059023A1 (fr) 2019-09-26 2021-04-01 Abionyx Pharma Sa Composés utiles pour le traitement des maladies du foie
WO2022061348A1 (fr) 2020-09-16 2022-03-24 Biotheryx, Inc. Agents de dégradation de protéine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
WO2022189856A1 (fr) 2021-03-08 2022-09-15 Abionyx Pharma Sa Composés utiles pour le traitement des maladies du foie
CN117177959A (zh) 2021-03-18 2023-12-05 赛本爱尔兰有限公司 裸头草碱类似物、盐、组合物和使用方法
WO2022195011A1 (fr) 2021-03-18 2022-09-22 Cybin Irl Limited Analogues de psilocybine, sels, compositions et procédés d'utilisation
WO2022243285A1 (fr) 2021-05-17 2022-11-24 Cybin Irl Limited Formulations de psilocybine
WO2022266249A1 (fr) 2021-06-16 2022-12-22 Biotheryx, Inc. Agents de dégradation de protéine kras, compositions pharmaceutiques associées, et leurs applications thérapeutiques
CA3222240A1 (fr) 2021-06-16 2022-12-22 Biotheryx, Inc. Agents de degradation de proteine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications therapeutiques
EP4387679A1 (fr) 2021-08-20 2024-06-26 Neurocrine Biosciences, Inc. Procédés de criblage d'inhibiteurs de vmat2
KR20240052775A (ko) 2021-09-08 2024-04-23 사이빈 아이알엘 리미티드 병용 약물 요법
WO2023135237A1 (fr) 2022-01-14 2023-07-20 Cybin Irl Limited Compositions de tryptamine et procédés
KR20240153566A (ko) 2022-02-15 2024-10-23 사이빈 아이알엘 리미티드 치료적 펜에틸아민 조성물, 및 사용 방법
KR20240153567A (ko) 2022-02-15 2024-10-23 사이빈 아이알엘 리미티드 펜에틸아민 유도체, 조성물, 및 사용 방법
EP4499087A1 (fr) 2022-03-31 2025-02-05 Cybin IRL Limited Combinaison d'oxyde nitreux et d'agonistes du récepteur 5-ht2a
IL316794A (en) 2022-05-10 2025-01-01 Biotheryx Inc CDK protease inhibitors, pharmaceuticals and therapeutic applications
WO2023247665A1 (fr) 2022-06-22 2023-12-28 Cybin Irl Limited Dispersions solides de psilocybine
EP4581013A1 (fr) 2022-08-31 2025-07-09 Cybin IRL Limited Composés de tryptamine, compositions et procédés d'utilisation
KR20250097837A (ko) 2022-10-28 2025-06-30 사이빈 아이알엘 리미티드 펜에틸아민 화합물, 조성물, 및 사용 방법
US20250082607A2 (en) 2023-02-27 2025-03-13 Cybin Irl Limited Methods of treating disorders with a psilocybin analog
WO2025006008A1 (fr) 2023-06-28 2025-01-02 Florascience Inc. Compositions et procédés comprenant du cannabinol pour réduire les troubles du sommeil et traiter des troubles du sommeil
WO2025099181A1 (fr) 2023-11-07 2025-05-15 HMNC Holding GmbH Régime de maintenance pour l'administration de 2-(2-chlorphényl)-2-(méthylamino)cyclohexane-1-one
WO2025099182A1 (fr) 2023-11-07 2025-05-15 HMNC Holding GmbH Régime d'induction pour l'administration de 2-(2-chlorphényl)-2-(méthylamino)cyclohexane-1-one

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL7014338A (fr) * 1970-09-30 1972-04-05
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760804A (en) * 1971-01-13 1973-09-25 Alza Corp Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US4002458A (en) * 1971-11-08 1977-01-11 Minnesota Mining And Manufacturing Company Controlled release capsules
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4356969A (en) * 1976-11-01 1982-11-02 Moleculon Research Corporation Vapor dispenser and method of making same
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4356696A (en) * 1980-04-04 1982-11-02 The Garrett Corporation Turbocharger combustor system
US4340054A (en) * 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4781714A (en) * 1983-11-02 1988-11-01 Alza Corporation Dispenser for delivering thermo-responsive composition
US4605165A (en) * 1984-06-13 1986-08-12 International Flavors & Fragrances Inc. Constant rate volatile composition dispensing article and process for using same
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4756844A (en) * 1986-12-29 1988-07-12 The Dow Chemical Company Controlled-release composition having a membrane comprising submicron particles
US4871542A (en) * 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US4915301A (en) * 1988-11-15 1990-04-10 International Flavors & Fragrances, Inc. Container with sorbent member and microporous membrane for dispensing vapor from volatile liquid
EP0550641B1 (fr) * 1990-09-28 1994-05-25 Pfizer Inc. Dispositif de distribution contenant un milieu hydrophobe
EP0607321A1 (fr) * 1991-10-10 1994-07-27 Alza Corporation Dispositifs de perfusion osmotique de medicaments utilisant des materiaux de paroi hydrophobes
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
WO1994023765A1 (fr) * 1993-04-21 1994-10-27 Sara Lee/De N.V. Dispositif de diffusion en continu d'une substance active dans l'atmosphere
DE69425828T2 (de) * 1993-07-22 2001-02-08 Pfizer Inc., New York Osmotische vorrichtung mit dampfdurchlaessiger beschichtung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037959A3 (fr) * 1997-02-24 1998-11-12 Willuweit Thomas Dispositif de distribution dosee de substances
WO2000023663A1 (fr) 1998-10-21 2000-04-27 Reckitt Benckiser (Uk) Limited Distributeur
US6510561B1 (en) 1998-10-21 2003-01-28 Reckitt Benckiser (Uk) Limited Dispensing device
AU765181B2 (en) * 1998-10-21 2003-09-11 Reckitt Benckiser (Uk) Limited Dispensing device

Also Published As

Publication number Publication date
AR002473A1 (es) 1998-03-25
WO1996041621A3 (fr) 1997-03-27
AU6107096A (en) 1997-01-09
ZA965030B (en) 1997-01-28
US5798119A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
US5798119A (en) Osmotic-delivery devices having vapor-permeable coatings
US4976966A (en) Delayed release osmotically driven fluid dispenser
US4445641A (en) Controlled-release dispenser
JP2701977B2 (ja) 疎水性媒体を含有する投薬体
JP2847326B2 (ja) 支持された液体膜送達デバイス
JP2853903B2 (ja) 蒸気透過性コーチングを有する浸透デバイス
US4034756A (en) Osmotically driven fluid dispenser
US4235236A (en) Device for dispensing drug by combined diffusional and osmotic operations
US5226902A (en) Pulsatile drug delivery device using stimuli sensitive hydrogel
EP0254394B1 (fr) Forme de dosage pour administrer un médicament contenant des moyens de régulation de la solubilité
EP0089548B1 (fr) Dispositif osmotique pour libérer une substance active
IE44450B1 (en) Osmotically driven dispenser and process for making same
HK1040197B (zh) 具有延长胃滞留作用之可膨胀的胃滞留性治疗系统
JPS6059203B2 (ja) 積層型ディスペンサ−の製造法
NO171004B (no) Fremgangsmaate for fremstilling av en utleveringsanordningsom i naervaer av en opploesningsvaeske frigir en biologisk aktiv bestanddel ved en i praksis konstant hastighet under en utvidet tidsperiode
PT98571B (pt) Dispositivos para a libertacao controlada que utilizam membranas polimerizadas interfacialmente e de processos para a sua preparacao
PT88565B (pt) Dispositivo para fornecimento de droga de solubilidade modulada
JP2012501233A (ja) 有益薬剤を一定速度で送出するための装置および方法
EP0325492B1 (fr) Dispositif osmotique pour délivrer des solutions diluées
US4145408A (en) Controlled release article
JP2003534496A (ja) 作動装置
JPH0347243B2 (fr)
JPH05201819A (ja) フェロモン製剤を用いた交信撹乱方法
Smith et al. Controlled release
JPH0124126B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP KR MX NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP KR MX NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA